News | Contrast Media | December 09, 2016

Bracco Diagnostics Highlights Contrast Media Milestones at RSNA 2016

Company received several key FDA approvals, including first contrast agent for liver ultrasound in adult and pediatric patients, first syringe-less power injector

 

contrast media

At the 2016 Annual Meeting of the Radiological Society of North America (RSNA 2016), Bracco Diagnostics Inc. showcased a review of key milestones the company has achieved this year in diagnostic imaging and contrast media.

The following summary provides a snapshot of major milestones impacting Bracco this year:

  • U.S. Food and Drug Administration (FDA) approval and recent launch of the first and only syringe-less power injector in the United States, designed to streamline workflow and improve patient care for computed tomography (CT);
  • The company received the first FDA approval for contrast-enhanced ultrasonography of the liver in adult and pediatric patients — the first ultrasound contrast agent approved for use in pediatrics in the world. This year, the Centers for Medicare & Medicaid Services approved coverage and coding for abdominal ultrasound with contrast under the Hospital Outpatient Prospective Payment System;
  • The company received the first and only FDA approvals of two of its barium-based products (one for CT; one for contrast radiography);
  • The company received an Innovative Technology Designation from Vizient for its injectable suspension for contrast echocardiography; and
  • Virtual colonoscopy received the highest grade from the U.S. Preventive Services Task Force as an alternative screening tool in detecting colorectal cancer. The recommendation was made after the task force found that CT colonography was proven to reduce the incidence and mortality of colorectal cancer, the second deadliest cancer in the U.S. Bracco markets the latest CO2 insufflator and a stool marker, or "fecal tagging" agent, for CT colonoscopy.

For more information: www.imaging.bracco.com/us-en

Related Content

The Global Contrast Injectors Market will grow by $613.47M during 2020-2024, according to Technavio
News | Contrast Media Injectors | June 17, 2020
June 17, 2020 — Technavio has been monitoring the ...
The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

Getty Images

News | Contrast Media | June 01, 2020
June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for...
Researchers from Tokyo Metropolitan University have surveyed the amount of gadolinium found in river water in Tokyo. Gadolinium is contained in contrast agents given to patients undergoing medical magnetic resonance imaging (MRI) scans, and it has been shown in labs to become toxic when exposed to ultraviolet rays. The researchers found significantly elevated levels, particularly near water treatment plants, highlighting the need for new public policy and removal technologies as MRI become even more commonp

Samples were taken along rivers around Tokyo. Measurements of rare earth element quantities indicate a clearly elevated amount of gadolinium compared to that in natural shale. Graphics courtesy of Tokyo Metropolitan University

News | Magnetic Resonance Imaging (MRI) | May 26, 2020
May 26, 2020 — Researchers from Tokyo Metropolitan...
Gadolinium-based contrast agents

UT Dallas faculty members who collaborated with Dr. Jeremiah Gassensmith (center, back), associate professor of chemistry and biochemistry, include Dr. Lloyd Lumata (left, back), assistant professor of physics, and Dr. Steven Nielsen, associate professor of chemistry. Chemistry graduate students in Gassensmith’s lab include (from left, front) Oliva Brohlin, Arezoo Shahrivarkevishahi and Laurel Hagge.

News | Contrast Media | February 06, 2020
February 6, 2020 — University of Texas at Dallas researchers
This image is of an 80 kg woman with a newly diagnosed IDH-wildtype glioblastoma

This image is of an 80 kg woman with a newly diagnosed IDH-wildtype glioblastoma. The quarter dose image on the left was obtained after the administration of 4 ml of MultiHance. Subsequently, an additional 12 ml of MultiHance was administered and the cumulative full dose image in the center was obtained. The image on the right was rendered following artificial intelligence processing of the 4 ml image using eGad genetic algorithms. This image has the quality of triple dose gadolinium even though only one quarter dose gadolinium was given.

Feature | Contrast Media Injectors | January 30, 2020 | By Matthew Kuhn, M.D., FACR
Gadolinium-based contrast agents (...

Image courtesy of Guerbet

Feature | Contrast Media Injectors | January 30, 2020 | By Melinda Taschetta-Millane
Contrast media injector technology has seen several recent advances, such as cutting costs by reducing contrast waste
Gadolinium based contrast dye in brain MRI

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | January 17, 2020
January 17, 2020 — Bracco Diagnostics Inc., the U.